These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 19943204)

  • 1. Combination chemotherapy for head and neck cancer: the addition of Bcl-2 inhibitors.
    Lo Russo L; Lo Muzio L
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1325-33. PubMed ID: 19943204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined evaluation of expression of telomerase, survivin, and anti-apoptotic Bcl-2 family members in relation to loss of differentiation and apoptosis in human head and neck cancers.
    Sharma H; Sen S; Mathur M; Bahadur S; Singh N
    Head Neck; 2004 Aug; 26(8):733-40. PubMed ID: 15287041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy.
    Giatromanolaki A; Koukourakis M; Zaramboukas T; Skordalaki A; Arapantoni P; Georgoulias V; Fountzilas G
    Anticancer Res; 1998; 18(6B):4685-92. PubMed ID: 9891541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Ginsberg L; Lawhorn K; Hong WK; Lippman SM
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-33-S19-37. PubMed ID: 9427263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.
    Giatromanolaki A; Koukourakis MI; Sivridis E; Fountzilas G
    Anticancer Res; 2000; 20(2A):997-1004. PubMed ID: 10810387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck.
    Fouret P; Temam S; Charlotte F; Lacau-St-Guily J
    Br J Cancer; 2002 Dec; 87(12):1390-5. PubMed ID: 12454767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.
    Recondo G; Armand JP; Tellez-Bernal E; Domenge C; Belehradek M; De Vathaire F; Wibault P; Richard JM; Cvitkovic E
    Laryngoscope; 1991 May; 101(5):494-501. PubMed ID: 1709437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expanding role of systemic therapy in head and neck cancer.
    Cohen EE; Lingen MW; Vokes EE
    J Clin Oncol; 2004 May; 22(9):1743-52. PubMed ID: 15117998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution.
    Adelstein DJ; Saxton JP; Rybicki LA; Esclamado RM; Wood BG; Strome M; Lavertu P; Lorenz RR; Carroll MA
    J Clin Oncol; 2006 Mar; 24(7):1064-71. PubMed ID: 16505425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel-based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinoma: current and future directions.
    Shin DM; Lippman SM
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):100-5. PubMed ID: 10190789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemotherapy of head and neck cancer].
    Kohno N; Nakazawa E; Kusunoki M; Nishiya M
    Gan To Kagaku Ryoho; 1996 Feb; 23(3):277-82. PubMed ID: 8712819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
    Corvò R
    Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.).
    Galetta D; Giotta F; Rosati G; Gebbia V; Manzione L; Di Bisceglie M; Borsellino N; Colucci G
    Anticancer Res; 2005; 25(6C):4445-9. PubMed ID: 16334124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
    Rodriguez-Pinilla M; Rodriguez-Peralto JL; Hitt R; Sanchez JJ; Ballestin C; Diez A; Sanchez-Verde L; Alameda F; Sanchez-Cespedes M
    Clin Cancer Res; 2004 Dec; 10(24):8486-92. PubMed ID: 15623629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction chemotherapy as initial treatment for advanced head and neck cancer: a model for the multidisciplinary treatment of solid tumors.
    Clark JR; Fallon BG; Frei E
    Important Adv Oncol; 1987; ():175-95. PubMed ID: 3331380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of squamous cell carcinoma of the head and neck with multi-drug chemotherapy and radiotherapy].
    Nishio M; Kagami Y; Narimatsu N; Asano K; Sanbe S; Somekawa Y
    Gan To Kagaku Ryoho; 1989 Sep; 16(9):3111-8. PubMed ID: 2476971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
    Adamo V; Ferraro G; Pergolizzi S; Sergi C; Laudani A; Settineri N; Alafaci E; Scimone A; Spano F; Spitaleri G
    Oral Oncol; 2004 May; 40(5):525-31. PubMed ID: 15006626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of combination chemotherapy with nedaplatin and 5-FU for head and neck squamous cell carcinoma].
    Yamaoka H; Tsukuda M; Enomoto H; Kawai S; Mikami Y; Arai Y; Nagahara T; Mochimatsu I
    Gan To Kagaku Ryoho; 2001 Sep; 28(9):1245-9. PubMed ID: 11579634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.